(Q39456707)

12 September 2017

title

Projected cost-effectiveness of primary angioplasty for acute myocardial infarction (English)

1 reference

12 September 2017

main subject

myocardial infarction

1 reference

1 reference

6

Weinstein MC

1 reference

12 September 2017

Lieu TA

1

1 reference

12 September 2017

Gurley RJ

2

1 reference

12 September 2017

Lundstrom RJ

3

1 reference

12 September 2017

Ray GT

4

1 reference

12 September 2017

Fireman BH

5

1 reference

12 September 2017

Parmley WW

7

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

Journal of the American College of Cardiology

12 September 2017

published in

1 reference

12 September 2017

volume

30

1 reference

12 September 2017

issue

7

1 reference

12 September 2017

page(s)

1741-1750

1 reference

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Coronary angioplasty. Statewide experience in California

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

The relationship between coronary angioplasty procedure volume and major complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Initial cost of primary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Use of direct angioplasty for treatment of patients with acute myocardial infarction in hospitals with and without on-site cardiac surgery. The Myocardial Infarction, Triage, and Intervention Project Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Cost and quality of life: thrombolysis and primary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Efficacy of percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction complicated by cardiogenic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Shock after acute myocardial infarction. A clinical and hemodynamic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Coronary angioplasty in acute myocardial infarction: primary, immediate adjunctive, rescue, or deferred adjunctive approach?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Patient preferences for stroke outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Accounting for Future Costs in Medical Cost-Effectiveness Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Very early thrombolytic therapy in suspected acute myocardial infarction. The Thrombolysis Early in Acute Heart Attack Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Long-term survival in 618 patients from the Western Washington streptokinase in myocardial infarction trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Late outcome after percutaneous transluminal coronary angioplasty during acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2897%2900391-4

7 January 2021

10.1016/S0735-1097(97)00391-4

Identifiers

DOI

1 reference

12 September 2017

1 reference